← Back to all trials
Active Not Recruiting
NCT06660394
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
Conditions: Dravet Syndrome
Sex: All
Ages: 2 Years – 65 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 108
Sponsor: Longboard Pharmaceuticals
Location: Arkansas Children's Hospital - Cardiology Clinic Little Rock Arkansas
Summary
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of DS must fulfill all of the following criteria:
1. Participants with seizure onset age \>1 and \
Source: ClinicalTrials.gov (NCT06660394). StuddyBuddy aggregates publicly available trial information.
